



# WEEKLY WRAP-UP

19<sup>TH</sup> JANUARY - 23<sup>RD</sup> JANUARY 2026

**PROGRESSIVE**<sup>®</sup>  
Your Progress Our Priority...

Equities | Derivatives | Commodities | Currency | PMS | Depository | Mutual Funds | NBFC | e-Broking



## HIGHLIGHTS OF THE WEEK

19 Jan 2026-23 Jan 2026

### DOMESTIC:

- HPCL to begin crude processing at Barmer refinery by end of month
- Indus Towers to set up subsidiary in GIFT city
- Zydus launches biosimilar for treatment of multiple cancers
- Fujiyama commissions Rs300cr solar cell project in UP to support in-house capabilities
- Ashoka Buildcon wins Rs308cr contract to build signature bridge in Daman
- Reliance set to buy sanctions-compliant Russian oil in February, March heat
- Persistent Systems looks to grow in Europe as macro headwinds linger
- CIL dispatches record 375MT coal via rail with third-party sampling
- Ceigall India bags Rs2,160cr NHAI road project in Bihar
- Senco Gold to acquire 68% stake in Melorra parent for Rs68cr
- Vedanta grants Rs2,500cr stock options over 5 years
- Tech Mahindra wins a USD500mn plus deal from Europe's Telefónica O2
- BPCL leads push to lock in long-term Middle East crude oil purchases
- Raymond Realty launches Rs5,000cr residential project in Mumbai's Wadala
- Bank of Baroda collaborates with IIFCL to boost infrastructure financing
- Adani Group unveils USD66bn Maharashtra investment plan at WEF 2026
- L&T Vyoma conducts ground breaking ceremony of its 40mw data centre
- CESC's green arm to invest Rs3,800cr in Uttar Pradesh solar plant
- Lupin signs licensing pact with Galenicum Health for injectable Semaglutide
- Embassy Developments plans Rs4,500cr investment in new Mumbai projects
- Tata Motors bets big on GST 2.0 tailwind with new electric and ICE trucks lineup
- Sunteck Realty acquires 2-acre land in Mumbai's Andheri through distress deal
- Lodha signs MoU with Maharashtra to invest Rs1trn in data centre park
- CCI approves Tata Steel's acquisition of 50.01% stake in Thriveni Pellets
- PowerGrid to procure reactors, transformers worth Rs914cr
- JSW Energy secures approval for Rs750cr preferential issue
- NALCO plans Rs1,500-2,000cr push to extract critical minerals from red mud, fly ash
- Everstone to sell entire stake in India's Burger King operator Restaurant Brands Asia

### ECONOMY:

- India to stay fastest-growing major economy despite global risks: RBI
- FPIs bank on options to raise gains from market fall
- IMF raises India FY26 growth estimate by 70bps to 7.3%

### INDUSTRY:

- CAFE norms to be finalised within 8 days
- Budget 2026: Railways to allocate higher funds for advanced coaches, safety systems
- Bangladesh Textile Mills Association announces indefinite shutdown of all textile mills from 01st February

## HIGHLIGHTS OF THE WEEK

19 Jan 2026-23 Jan 2026

### COVERAGE NEWS:

**Engineers India Ltd:** The Dangote Group has signed a contract with EIL worth USD350mn+ to engage EIL as PMC and EPCM consultant to expand its refining capacity from 650,000 barrels per day to 1.4 million barrels per day.

**Bharat Rasayan Ltd:** The Board of Directors have approved the change in designation of Shri Rajender Prasad Gupta from Executive Director to Non-Executive, Non-Independent Director, with effect from 19th January, 2026.

**Paushak Ltd:** The company has initiated the process for commissioning its new multi-purpose plant (for an investment of Rs1750mn) in a phased manner for certain derivatives with associated infrastructure.

**RSWM Ltd:** The company has executed a SPA with M/s Bhilwara Energy Limited and M/s LNJ Greenpet Private Limited for acquisition of 20.01mn equity shares of FV of Rs10 each for a total purchase consideration of approx. Rs200mn

**Sterlite Technologies Ltd:** The company has successfully completed the trial of Multi-Core Fibre (MCF) with Colt Technology Services (UK) across its London metro optical network.

**Sun Pharmaceutical Industries Ltd:** The company alongwith its subsidiaries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of Semaglutide injection under the brand name, Noveltreat (0.25mg/0.5mL, 0.5mg/0.5mL, 1mg/0.5mL, 1.7mg/0.75mL and 2.4mg/0.75mL, with a maintenance dose of 2.4mg once weekly), after the expiry of Semaglutide patent in India.


## HIGHLIGHTS OF THE WEEK

19 Jan 2026-23 Jan 2026

### NIFTY 50 COMPONENTS (WEEKLY PERFORMANCE)

|                   |          |                |         |                 |          |
|-------------------|----------|----------------|---------|-----------------|----------|
| Adani Enterprises | (13.77%) | HDFC Life      | (2.89%) | Reliance        | (5.07%)  |
| Adani Ports       | (7.68%)  | Hindalco       | 2.04%   | SBI Life        | (3.62%)  |
| Apollo Hospital   | (5.77%)  | HUL            | 1.87%   | SBIN            | (1.17%)  |
| Asian Paints      | (1.90%)  | ICICI Bank     | (4.74%) | ShriRam Finance | 0.81%    |
| Axis Bank         | (3.25%)  | Indigo         | (0.41%) | Sun Pharma      | (2.28%)  |
| Bajaj Auto        | (0.69%)  | INFY           | (1.01%) | Tata Consumer   | (2.78%)  |
| Bajaj Finserv     | (2.35%)  | ITC            | (1.82%) | Tata Steel      | (0.21%)  |
| Bajaj Finance     | (2.26%)  | JioFin         | (8.90%) | TCS             | (1.62%)  |
| BEL               | 0.44%    | JSW Steel      | (1.90%) | Tech Mahindra   | 1.72%    |
| Bharti Airtel     | (1.49%)  | Kotak Bank     | 1.31%   | TITAN           | (4.15%)  |
| Cipla             | (5.41%)  | LT             | (2.77%) | TMPV            | (2.54%)  |
| Coal India        | (3.12%)  | M&M            | (2.87%) | Trent           | (3.90%)  |
| Dr. Reddy's Labs  | 5.15%    | Maruti         | (2.25%) | UltraTech       | (0.25%)  |
| Eicher Motors     | (4.52%)  | Max Healthcare | (4.07%) | Wipro           | (10.78%) |
| Eternal           | (9.70%)  | Nestle India   | (1.50%) |                 |          |
| Grasim            | (1.60%)  | NTPC           | (2.66%) |                 |          |
| HCL Tech          | 0.60%    | ONGC           | (0.46%) |                 |          |
| HDFC Bank         | (1.59%)  | PowerGrid      | (1.24%) |                 |          |

### SECTORAL PERFORMANCE



## HIGHLIGHTS OF THE WEEK

19 Jan 2026-23 Jan 2026

### DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

### Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai-400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500

### Compliance Officer:

Ms. Mamatha Poojari,  
Email: compliance@progressiveshares.com,  
Contact No.:022-40777500

### Grievance Officer:

Email: grievancecell@progressiveshares.com